Madrigal Pharmaceuticals, Inc.
Complete enrollment in the 52-week serial liver biopsy population of MAESTRO-NASH
Delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 25 Feb 2021
- Due
- 30 Jun 2021
- Delivered
- 30 Jun 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“completion of enrollment in the 52-week, serial liver biopsy population for Subpart H approval of MAESTRO-NASH, which we expect to complete in the second quarter”
What we found
Evidence strength A What the grades mean
A later 10-Q says the company announced on June 30, 2021 that it achieved target enrollment to support the planned Subpart H submission, consistent with the deadline. The filing does not explicitly name the serial biopsy population.
-
A Madrigal Pharmaceuticals, Inc. 10-Q filed 2021-08-05
“On June 30, 2021 we announced achievement of target enrollment of patients to support the planned Subpart H (Accelerated Approval of New Drugs for Serious or Life-Threatening Illnesses) submission to the US Food and Drug Administration (FDA).” ✓ confirmed on the page
-
A Madrigal Pharmaceuticals, Inc. 10-Q filed 2021-11-04
“On June 30, 2021 we announced our achievement of the requisite enrollment of patients to support the planned Subpart H (Accelerated Approval of New Drugs for Serious or Life-Threatening Illnesses) submission to the US Food and Drug Administration (FDA).” ✓ confirmed on the page
-
A Madrigal Pharmaceuticals, Inc. 10-Q filed 2022-05-09
“A second liver biopsy at week 52 in the first 900 patients will be the basis of filing for accelerated approval under subpart H of applicable FDA regulations” ✓ confirmed on the page
Checked 26 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Complete
- Deliverable
- Enrollment in 52-week biopsy population of MAESTRO-NASH
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Madrigal Pharmaceuticals, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-MDGL-024497 · Corrections policy